Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method.
The US Food and Drug Administration's (FDA's) guidance for industry on dissolution testing of immediate-release solid oral dosage forms describes that drug dissolution may be the rate limiting step for drug absorption in the case of low solubility/high permeability drugs (BCS class II drugs). US FDA Guidance describes the model-independent mathematical approach proposed by Moore and Flanner for calculating a similarity factor (f2) of dissolution across a suitable time interval. In the present study, the similarity factor was calculated on dissolution data of two marketed aceclofenac tablets (a BCS class II drug) using various weighing approaches proposed by Gohel et al. The proposed approaches were compared with a conventional approach (W = 1). On the basis of consideration of variability, preference is given in the order of approach 3 > approach 2 > approach 1 as approach 3 considers batch-to-batch as well as within-samples variability and shows best similarity profile. Approach 2 considers batch-to batch variability with higher specificity than approach 1.
Soni
T G
TG
Anand Pharmacy College, Gujarat, India. tejalsoni_2973@yahoo.com
Desai
J U
JU
Nagda
C D
CD
Gandhi
T R
TR
Chotai
N P
NP
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000032:analysis* / Q000592:standards*; D002626:Chemistry, Pharmaceutical; D003627:Data Interpretation, Statistical; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis / Q000592:standards; D015203:Reproducibility of Results; D012995:Solubility; D013607:Tablets
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013607:Tablets; D004008:Diclofenac; C056498:aceclofenac